← Back to Search

Other

Lithium for Parkinson's Disease

Phase 1 & 2
Recruiting
Research Sponsored by State University of New York at Buffalo
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up throughout 24 week study

Summary

This trial will investigate how taking lithium 20mg/day affects MRI scans and blood tests in 20 people with early-stage Parkinson's disease, compared to those who take a placebo.

Who is the study for?
This trial is for early-stage Parkinson's disease patients who haven't used lithium before and have no other neurological conditions. Participants should not be tobacco or THC users, must have stable PD medications for over a month, and cannot have any active medical issues that could affect the study.
What is being tested?
The study is testing if a low dose of lithium (20mg/day) can impact MRI and blood biomarkers in Parkinson's disease compared to a placebo. It involves 20 participants with early-stage PD to see if there are any benefits.
What are the potential side effects?
While not specified here, common side effects of lithium may include increased thirst, hand tremors, frequent urination, mild nausea or diarrhea; however individual experiences may vary.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~throughout 24 week study
This trial's timeline: 3 weeks for screening, Varies for treatment, and throughout 24 week study for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
MRI-derived free water (FW) levels.
Peripheral blood mononuclear cell (PBMC) nuclear receptor-related 1 protein (Nurr1) mRNA expression
Serum neurofilament light chain (NfL)
Secondary study objectives
Fatigue Severity Scale
Geriatric Depression Scale-15
Insomnia Severity Index
+10 more
Other study objectives
Adverse events

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: LithiumActive Control1 Intervention
Lithium: 10mg, 2x/day
Group II: PlaceboPlacebo Group1 Intervention
Identical capsules filled with cellulose: 10mg, 2x/day

Find a Location

Who is running the clinical trial?

State University of New York at BuffaloLead Sponsor
268 Previous Clinical Trials
52,310 Total Patients Enrolled
The Cure Parkinson's TrustUNKNOWN
2 Previous Clinical Trials
86 Total Patients Enrolled
~13 spots leftby Aug 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top